35 Gatehouse Drive
About Arrakis TherapeuticsArrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines. Our goal is to interrogate and exploit the vast and largely unexplored transcriptome—the full collection of RNAs transcribed from DNA—to discover small-molecule medicines that target RNA at key disease intervention points.
Founder: Raj Parekh, Ph.D.
Founder and CSO: Russell C. Petter, Ph.D.
CEO and Chairman: Michael Gilman, Ph.D.
CBO: Daniel Koerwer
Senior VP, Biology: James Barsoum, Ph.D.
Please click here for Arrakis Therapeutics' job opportunities.
8 articles with Arrakis Therapeutics
4/19/2019Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.
Arrakis Therapeutics Announces $75 Million Series B Financing to Advance a New Class of Small-Molecule Medicines Targeting RNA
Having established first-in-industry RNA-targeted Small Molecule (rSM) platform, Arrakis will focus pipeline in oncology and genetically validated targets in other diseases
The funding will allow Arrakis to realize its vision of creating a new class of medicines with RNA-targeted small molecules, or rSMs.
Ribometrix closed on a Series A financing worth $30 million. The round was led by M Ventures, with participation of new investors Amgen Ventures, Pappas Capital and Illumina Ventures.
Arrakis is pioneering the discovery of a new class of medicines called RNA-targeted small molecules, or rSMs
Arrakis Therapeutics Announces Exclusive License to RNA-targeted Small Molecule Technology From the University of Pennsylvania
The license allows utilization of technology related to families of compounds that selectively bind specific nucleic acid structures, called three-way junctions.
Arrakis Therapeutics announced that it has released SHAPEware as open-source software for the research community with the goal of promoting and facilitating the use of SHAPE-based approaches to study RNA structure.
Biotech Vets Launch Arrakis Therapeutics With $38 Million and Will be Helmed By Biogen Alum Michael Gilman